Mission BioCapital

Mission BioCapital is a venture capital firm specializing in early-stage life science investments, providing capital, shared laboratory space, and comprehensive support to biotech entrepreneurs. The firm targets therapeutics, diagnostics, biotechnology tools, and related innovations, emphasizing a collaborative model that accelerates progress from discovery to clinical milestones. Through its Platinum Program, Mission BioCapital offers up to $500,000 in non-dilutive funding, guaranteed lab benches in affiliated incubators across 19 cities in the US and Europe, drug discovery services from partners like Alloy Therapeutics and HitGen, legal advising from Goodwin, and mentorship from its network including Lilly. Founded in 2009, Mission BioCapital resulted from the merger of BioInnovation Capital and Mission Bay Capital around 2015, combining expertise in life science investing. Now investing from its fifth fund, Mission BioCapital V, raised at $275 million in 2021, the firm has backed over 55 companies and completed 25 deals in the last two years. Notable portfolio companies include Dren Bio, Alessa Therapeutics, SiteOne Therapeutics, Sound Agriculture, Circle Pharma, and March Biosciences, spanning seed to series C rounds. The team comprises scientists, serial entrepreneurs, and investors with deep operational experience in biotech. Key leaders include Managing General Partners Douglas Crawford, Sarika Temme-Bapat, Loretta McClary, and Steve Tregay; Partners like Robert Blazej and Cassidy Blundell; and Founder Johannes Fruehauf. Many hold PhDs in bioengineering or related fields and serve on boards of portfolio firms such as Telo Therapeutics and Progentos Therapeutics. With offices in San Francisco and Cambridge, and expansion into Europe including Copenhagen, Mission BioCapital supports founders from idea to exit, fostering innovation through shared labs like MBC BioLabs, LabCentral, and BioLabs.